• 1. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 2. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 5. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283

• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthalenes Naphthalenecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthalenes Naphthalenecarboxylic acids and derivatives Naphthalenecarboxylic acids

Ethyl 4-(benzyloxy)-7-bromo-2-naphthoate: A Key Intermediate in Modern Pharmaceutical Synthesis

Ethyl 4-(benzyloxy)-7-bromo-2-naphthoate, with the CAS number 178877-03-7, is a significant compound in the realm of pharmaceutical chemistry. This compound serves as a crucial intermediate in the synthesis of various bioactive molecules, particularly those targeting neurological and inflammatory disorders. Its unique structural features, including the presence of a bromine substituent and a benzyloxy group, make it a versatile building block for medicinal chemists.

The structural motif of Ethyl 4-(benzyloxy)-7-bromo-2-naphthoate consists of a naphthalene core, which is a common scaffold in many pharmacologically active agents. The naphthalene ring system is particularly valued for its ability to interact with biological targets through hydrophobic and π-stacking interactions. The introduction of the bromine atom at the 7-position enhances the reactivity of the molecule, allowing for further functionalization via cross-coupling reactions such as Suzuki-Miyaura and Buchwald-Hartwig couplings. These reactions are pivotal in constructing complex molecular architectures essential for drug development.

The benzyloxy group at the 4-position provides an additional layer of functionality, enabling selective modifications and protecting group strategies. This feature is particularly useful in multi-step syntheses where orthogonal reactions are required to achieve high yields and purity. The ethyl ester moiety at the 2-position not only influences the solubility and metabolic stability of derived compounds but also serves as a handle for further derivatization, such as hydrolysis to yield carboxylic acids or reduction to alcohols.

Recent advancements in pharmaceutical research have highlighted the importance of Ethyl 4-(benzyloxy)-7-bromo-2-naphthoate in developing novel therapeutics. For instance, studies have demonstrated its utility in synthesizing small-molecule inhibitors targeting enzymes involved in cancer metabolism. The bromine substituent facilitates palladium-catalyzed cross-coupling reactions, enabling the construction of aryl-aryl and aryl-heteroaryl bonds that are prevalent in many oncology drugs. Additionally, the benzyloxy group can be selectively removed under mild acidic conditions, allowing for the generation of more reactive intermediates that can be further functionalized.

In another area of research, Ethyl 4-(benzyloxy)-7-bromo-2-naphthoate has been employed in the development of anti-inflammatory agents. The naphthalene scaffold is known to exhibit anti-inflammatory properties by modulating immune responses through interactions with nuclear receptors such as peroxisome proliferator-activated receptors (PPARs). By leveraging the reactivity of the bromine and benzyloxy groups, researchers have been able to design molecules that exhibit potent anti-inflammatory activity while minimizing off-target effects. This underscores the compound's versatility as a pharmacophore in drug discovery.

The synthesis of Ethyl 4-(benzyloxy)-7-bromo-2-naphthoate itself is an elegant example of modern organic synthesis techniques. The starting materials can be readily obtained through established routes, and the reaction conditions are optimized for high yields and minimal byproduct formation. This efficiency is crucial in industrial settings where cost-effectiveness and scalability are paramount. Furthermore, green chemistry principles have been increasingly applied to its synthesis, reducing solvent usage and minimizing waste generation without compromising on product quality.

Future directions in the use of Ethyl 4-(benzyloxy)-7-bromo-2-naphthoate may explore its potential in other therapeutic areas, such as neurodegenerative diseases and infectious disorders. The ability to modify its core structure while retaining key pharmacological properties makes it an attractive candidate for structure-activity relationship (SAR) studies. By systematically altering substituents on the naphthalene ring or introducing new functional groups, researchers can uncover novel bioactivities and optimize drug-like properties such as solubility, bioavailability, and metabolic stability.

In conclusion, Ethyl 4-(benzyloxy)-7-bromo-2-naphthoate (CAS no. 178877-03-7) is a multifaceted compound with significant applications in pharmaceutical synthesis. Its unique structural features enable diverse chemical transformations, making it an indispensable tool for medicinal chemists. As research continues to uncover new therapeutic targets and synthetic methodologies, this compound will undoubtedly remain at the forefront of drug discovery efforts.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)